DeepMed Research

Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Safety and Effectiveness of a Silicone Hydrogel Custom Contact Lens When Compared to Alden Optical HP Sphere Lens

Not Applicable

Completed

Conditions: Contact Lens Wear

Interventions: Device: Alden Optical HP Sphere Contact Lens
Device: Custom Samfilcon B Contact Lenses
Device: ReNu MultiPlus Lubricating and Rewetting Drops
Device: Biotrue Multi-Purpose Solution

First Posted Date: 2019-04-01

Last Posted Date: 2022-11-14

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 84

Registration Number: NCT03897712

Locations: 🇺🇸
Bausch Site 5, Warrensburg, Missouri, United States
🇺🇸
Bausch Site 1, San Francisco, California, United States
🇺🇸
Bausch Site 6, Vestal, New York, United States

and more 4 locations

Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism

Not Applicable

Completed

Conditions: Astigmatism

Interventions: Device: Test
Device: Control

First Posted Date: 2018-09-24

Last Posted Date: 2021-01-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 242

Registration Number: NCT03681808

Locations: 🇺🇸
Bausch Site 117, Irvine, California, United States
🇺🇸
Bausch Site 102, Jacksonville, Florida, United States
🇺🇸
Bausch Site 108, San Jose, California, United States

and more 10 locations

Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens

Not Applicable

Completed

Conditions: Cataract

Interventions: Device: enVista MX60E
Device: enVista MX60EF

First Posted Date: 2018-07-27

Last Posted Date: 2024-12-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 501

Registration Number: NCT03603600

Locations: 🇺🇸
Bausch Site 118, Las Vegas, Nevada, United States
🇺🇸
Bausch Site 121, Sioux Falls, South Dakota, United States
🇺🇸
Bausch Site 119, Birmingham, Mississippi, United States

and more 20 locations

Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)

Not Applicable

Completed

Conditions: Cataract

Interventions: Device: Bausch & Lomb DVisc40
Device: Alcon VISCOAT®

First Posted Date: 2018-04-30

Last Posted Date: 2021-10-22

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 372

Registration Number: NCT03511638

Locations: 🇺🇸
Valeant Site 01, San Diego, California, United States

A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle

Phase 3

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: EM-100
Drug: Zaditor®
Drug: Vehicle

First Posted Date: 2018-04-06

Last Posted Date: 2023-06-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 65

Registration Number: NCT03489941

Locations: 🇺🇸
Total Eye Care, PA, Memphis, Tennessee, United States

Clinical Study of Approved Contact Lenses

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Senofilcon C
Device: Samfilcon A

First Posted Date: 2017-11-22

Last Posted Date: 2021-01-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 271

Registration Number: NCT03351101

Locations: 🇺🇸
Valeant Site 04, Denver, Colorado, United States
🇺🇸
valeant Site 02, San Diego, California, United States
🇺🇸
Valeant Site 03, San Francisco, California, United States

and more 8 locations

Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)

Phase 1

Completed

Conditions: Anaphylaxis

Interventions: Device: Part 1
Device: Part 2 Group 1
Drug: Part 2 group 2
Device: Part 2 group 3
Device: Part 2 Group 4

First Posted Date: 2017-09-14

Last Posted Date: 2019-06-21

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 43

Registration Number: NCT03282929

Locations: 🇩🇪
Nuvisan GmbH, Neu-Ulm, Wegenerstrasse 13, Germany

Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant

Completed

Conditions: Uveitis, Posterior

First Posted Date: 2017-05-09

Last Posted Date: 2019-06-21

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 3

Registration Number: NCT03145025

Locations: 🇺🇸
Valeant Site 001, Boston, Massachusetts, United States

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Loteprednol Etabonate

First Posted Date: 2017-04-04

Last Posted Date: 2017-05-18

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 15

Registration Number: NCT03098953

Locations: 🇺🇸
Valeant Site 01, Inglewood, California, United States

LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Phase 3

Completed

Conditions: Ocular Inflammation
Cataract
Pain

Interventions: Drug: Loteprednol Etabonate Ophthalmic Gel dosed TID
Drug: Loteprednol Etabonate Ophthalmic Gel dosed BID
Drug: Vehicle Gel

First Posted Date: 2016-06-01

Last Posted Date: 2021-01-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 600

Registration Number: NCT02786901

Locations: 🇺🇸
Valeant Site 01, Phoenix, Arizona, United States
🇺🇸
Valeant Site 02, Saint Louis, Missouri, United States
🇺🇸
Valeant Site 05, Miami, Florida, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy